Patents by Inventor David L. Berliner

David L. Berliner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5969168
    Abstract: The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors. The steroids are useful as ligands to neuroepithelial receptors in the human vomeronasal gland to stimulate autonomic and hypothalamic activity.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: October 19, 1999
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Patent number: 5965552
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Androstane steroid, or a pharmaceutical composition containing a semiochemical, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: October 12, 1999
    Assignee: Pherin Pharmaceuticals, Inc.
    Inventors: David L. Berliner, Nathan William Adams, Clive L. Jennings-White
  • Patent number: 5962443
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a 19-nor pregnane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: October 5, 1999
    Assignee: Pherin Corporation
    Inventors: Clive L. Jennings-White, David L. Berliner, Nathan W. Adams
  • Patent number: 5939570
    Abstract: The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: June 4, 1997
    Date of Patent: August 17, 1999
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Patent number: 5925774
    Abstract: The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: July 20, 1999
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Patent number: 5922699
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a 19-nor cholane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: July 13, 1999
    Assignee: Pherin Corporation
    Inventors: Clive L. Jennings-White, David L. Berliner, Nathan W. Adams
  • Patent number: 5883087
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Androstane steroid, or a pharmaceutical composition containing a semiochemical, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: May 28, 1996
    Date of Patent: March 16, 1999
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan William Adams, Clive L. Jennings-White
  • Patent number: 5849327
    Abstract: Diseases of the colon are treated by oral ingestion of a unit dosage form containing a plurality of porous microscopic beads, the pores containing an active agent or drug and plugged with a polysaccharide that is chemically degradable by colon-specific bacteria. The dosage form further contains a coating of an enteric material that remains intact until the dosage form reaches the colon.
    Type: Grant
    Filed: September 27, 1996
    Date of Patent: December 15, 1998
    Assignee: Advanced Polymer Systems, Inc.
    Inventors: David L. Berliner, Sergio Nacht
  • Patent number: 5817631
    Abstract: The invention is directed to the treatment of degenerative diseases of tissues which have lost melanin and which share a common embryological basis as tissues of the nervous system by the administration of an active substance which causes an increased concentration of melanin in the tissue. Such active substances include melanin, melanin variants, melanin analogs, melanin derivatives, tyrosinase, tyrosinase gene, melanin-concentrating hormone and combinations thereof. Examples of such diseases include Parkinson's disease, Alzheimer's disease, retinitis pigmentosa, schizophrenia and dementia. The invention is also useful in assisting in the repair of neurons in a mammal having neuron damage by administering an effective amount of an active substance which causes an increased concentration of melanin in the neuron to aid in nerve repair.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 6, 1998
    Assignee: Biosource Technologies, Inc.
    Inventors: David L. Berliner, Robert L. Erwin, David R. McGee
  • Patent number: 5792757
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a 19-nor pregnane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 11, 1998
    Assignee: Pherin Pharmaceuticals
    Inventors: Clive L. Jennings-White, David L. Berliner, Nathan William Adams
  • Patent number: 5783571
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Estrene steroid, or a pharmaceutical composition containing an Estrene steroid, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: September 28, 1993
    Date of Patent: July 21, 1998
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan William Adams, Clive L. Jennings-White
  • Patent number: 5776968
    Abstract: The invention is directed to the treatment of degenerative diseases of tissues which have lost melanin and which share a common embryological basis as tissues of the nervous system by the administration of an active substance which causes an increased concentration of melanin in the tissue. Such active substances include melanin, melanin variants, melanin analogs, melanin derivatives, tyrosinase, tyrosinase gene, melanin-concentrating hormone and combinations thereof. Examples of such diseases include Parkinson's disease, Alzheimer's disease, retinitis pigmentosa, schizophrenia and dementia. The invention is also useful in assisting in the repair of neurons in a mammal having neuron damage by administering an effective amount of an active substance which causes an increased concentration of melanin in the neuron to aid in nerve repair.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 7, 1998
    Assignee: Biosource Technologies, Inc.
    Inventors: David L. Berliner, Robert L. Erwin, David R. McGee
  • Patent number: 5703051
    Abstract: The invention is directed to the treatment of degenerative diseases of tissues which have lost melanin and which share a common embryological basis as tissues of the nervous system by the administration of an active substance which causes an increased concentration of melanin in the tissue. Such active substances include melanin, melanin variants, melanin analogs, melanin derivatives, tyrosinase, tyrosinase gene, melanin-concentrating hormone and combinations thereof. Examples of such diseases include Parkinson's disease, Alzheimer's disease, retinitis pigmentosa, schizophrenia and dementia. The invention is also useful in assisting in the repair of neurons in a mammal having neuron damage by administering an effective amount of an active substance which causes an increased concentration of melanin in the neuron to aid in nerve repair.
    Type: Grant
    Filed: December 10, 1992
    Date of Patent: December 30, 1997
    Assignee: Biosource Technologies, Inc.
    Inventors: David L Berliner, Robert L. Erwin, David R. McGee
  • Patent number: 5633392
    Abstract: The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: May 27, 1997
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Patent number: 5563131
    Abstract: The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e.g. a pregnane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.
    Type: Grant
    Filed: August 4, 1994
    Date of Patent: October 8, 1996
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Clive L. Jennings-White, Nathan W. Adams
  • Patent number: 5286979
    Abstract: This invention is a process for absorbing ultraviolet radiation in the atmosphere by dispersing melanin, its analogs, or derivatives into the atmosphere. By appropriate choice of melanin composition, size of melanin dispersoids, and their concentration, the melanin will absorb some quantity of ultraviolet radiation and thereby lessen its overall effect on the critters who would normally absorb such radiation.
    Type: Grant
    Filed: June 7, 1993
    Date of Patent: February 15, 1994
    Inventors: David L. Berliner, Helen Leong
  • Patent number: 5278141
    Abstract: The invention concerns novel, non-therapeutic fragrance compositions containing an odorant and a naturally occurring human pheromone. The invention also concerns fragrance compositions containing mixtures of naturally occurring human pheromones. The human pheromones disclosed are steroids which belong to two distinct chemical classes: 16-Androstenes and Estrenes.
    Type: Grant
    Filed: March 8, 1993
    Date of Patent: January 11, 1994
    Assignee: Erox Corporation
    Inventor: David L. Berliner
  • Patent number: 5272134
    Abstract: The invention concerns novel, non-therapeutic fragrance compositions and other compositions containing an odorant and a naturally occurring human pheromone. The invention also concerns fragrance compositions containing mixtures of naturally occurring human pheromones. The human pheromones disclosed are steroids which desirably belong to two distinct chemical classes: 16-Androstenes and Estrenes.
    Type: Grant
    Filed: June 24, 1992
    Date of Patent: December 21, 1993
    Assignee: Erox Corporation
    Inventor: David L. Berliner
  • Patent number: 5210076
    Abstract: The invention is directed to the treatment of degenerative diseases of tissues which have lost melanin and which share a common embryological basis as tissues of the nervous system by the administration of an active substance which causes an increased concentration of melanin in the tissue. Such active substances include melanin, melanin variants, melanin analogs, melanin derivatives, tyrosinase, tyrosinase gene, melanin-concentrating hormone and combinations thereof. Examples. of such diseases include Parkinson's disease, Alzheimer's disease, retinitis pigmentosa, schizophrenia and dementia. The invention is also useful in assisting in the repair of neurons in a mammal having neuron damage by administering an effective amount of an active substance which causes an increased concentration of melanin in the neuron to aid in nerve repair.
    Type: Grant
    Filed: November 5, 1990
    Date of Patent: May 11, 1993
    Inventors: David L. Berliner, Robert L. Erwin, David R. McGee